Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided: ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.

The present disclosure relates to a compound of Formula (I), a tautomer, a stereoisomer or a mixture of stereoisomers, a pharmaceutically acceptable salt, a hydrate, or a deuterated derivative thereof and their use in, e.g., treating a disease or disorder associated with CDK2. The present disclosure also relates to pharmaceutical compositions containing such compounds, and their use in treating or preventing a disease or disorder associated with CDK2.

The present disclosure relates to a compound of Formula (I), a tautomer, a stereoisomer or a mixture of stereoisomers, a pharmaceutically acceptable salt, a hydrate, or a deuterated derivative thereof and their use in, e.g., treating a disease or disorder associated with CDK2. The present disclosure also relates to pharmaceutical compositions containing such compounds, and their use in treating or preventing a disease or disorder associated with CDK2.

A compound of formula (I); [MCL-1 ligand moiety]-[linker]-[ligase ligand moiety] (I); or a salt, solvate, hydrate, isomer or prodrug thereof, wherein [MCL-1 ligand moiety] is a compound of Formula (A), Formula (B) or Formula (C), and its use in the treatment of cancer.

##STR00001##

Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.

Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.

Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided, ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.

Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided, ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.

The present invention provides an application of an SARM1 enzyme activity inhibitor in the treatment of neurodegenerative diseases or neurological diseases or conditions. The present invention particularly provides a compound of formula I as an SARM1 enzyme activity inhibitor and a pharmaceutical composition thereof.

##STR00001##

Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided,

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.